NewLink Genetics Corporation (NLNK) Releases Earnings Results, Beats Estimates By $0.07 EPS
NewLink Genetics Corporation (NASDAQ:NLNK) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.69) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.07, reports. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%.
A number of equities analysts recently weighed in on NLNK shares. ValuEngine cut NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Jefferies Group LLC set a $7.00 price objective on NewLink Genetics Corporation and gave the company a “hold” rating in a report on Friday, August 25th. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics Corporation in a report on Friday, September 8th. Bank of America Corporation started coverage on NewLink Genetics Corporation in a report on Friday, October 13th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Stifel Nicolaus raised their price objective on NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a report on Monday, September 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $25.83.
In related news, major shareholder Stine Seed Farm, Inc. acquired 780,487 shares of the firm’s stock in a transaction on Friday, October 6th. The shares were acquired at an average cost of $10.25 per share, for a total transaction of $7,999,991.75. Following the completion of the transaction, the insider now directly owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 13.70% of the company’s stock.
A hedge fund recently raised its stake in NewLink Genetics Corporation stock. State Street Corp raised its stake in shares of NewLink Genetics Corporation (NASDAQ:NLNK) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 391,464 shares of the biotechnology company’s stock after purchasing an additional 4,630 shares during the period. State Street Corp owned 1.33% of NewLink Genetics Corporation worth $2,875,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 55.09% of the stock is currently owned by institutional investors and hedge funds.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.